Literature DB >> 28695412

[Basis for the treatment of eczematous diseases in otorhinolaryngology].

R Fölster-Holst1, A Sperl2, T Albrecht3, L Klimek4.   

Abstract

According to Coombs and Gell, cell-mediated immune responses belong to type IV reactions and are borne mainly by T lymphocytes. The eliciting allergens are usually so-called haptens. Haptens are substances which develop to whole antigens only by binding to protein carriers. In otorhinolaryngology, delayed allergic hypersensitivities are apparent mainly as contact eczemata. Facial dermatitis, auricle and ear canal eczema as well as perioral eczema belong to the most common forms of contact dermatitis in ENT patients. The patient's medical history and morphology of the eczema give a strong indication for a proper diagnosis. Verification is carried out by patch test according to the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF, The Association of the Scientific Medical Societies in Germany) guidelines. Hereby the most widespread contact allergens are tested in a so-called "standard block", which can be reduced to an individualized allergen spectrum, based on medical history. For therapy, allergen avoidance is the most important measure which should also be applied prophylactically. Moreover, antiinflammatory treatment of the contact eczema is carried out with tapering topical corticosteroids. Depending on the patient's age, location and severity of the contact eczema, newer class II or III preparations should be chosen. Skin care preparations are helpful to reduce corticosteroid consumption and are indicated additionally after the acute phase treatment. An important differential diagnosis of contact eczema is atopic dermatitis. Whilst contact dermatitis experiences healing by avoiding the triggering noxious agent, genetically determined atopic dermatitis shows a chronic, recurrent course. In addition to topical corticosteroids, calcineurin inhibitors have been approved for treatment of atopic eczema. In all eczema diseases, regular skin care is a necessary measure which contributes mainly to barrier repair.

Entities:  

Keywords:  Allergy; Cell-mediated immunity; Contact eczema; Perioral dermatitis; Skin tests

Mesh:

Substances:

Year:  2017        PMID: 28695412     DOI: 10.1007/s00106-017-0383-3

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  20 in total

1.  Noninvasive stratum corneum sampling and electron microscopical examination of skin barrier integrity: pilot study with a topical glycerin formulation for atopic dermatitis.

Authors:  S Daehnhardt-Pfeiffer; C Surber; K-P Wilhelm; D Daehnhardt; G Springmann; M Boettcher; R Foelster-Holst
Journal:  Skin Pharmacol Physiol       Date:  2012-03-06       Impact factor: 3.479

2.  Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG).

Authors:  G Heine; A Schnuch; W Uter; M Worm
Journal:  Allergy       Date:  2006-05       Impact factor: 13.146

3.  Patch testing in children--recommendations of the German Contact Dermatitis Research Group (DKG).

Authors:  Margitta Worm; Werner Aberer; Monika Agathos; Detlef Becker; Jochen Brasch; Thomas Fuchs; Uwe Hillen; Peter Höger; Vera Mahler; Axel Schnuch; Christiane Szliska
Journal:  J Dtsch Dermatol Ges       Date:  2007-02       Impact factor: 5.584

4.  [A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)].

Authors:  A Schnuch; O Gefeller; W Uter
Journal:  Dtsch Med Wochenschr       Date:  2005-12-16       Impact factor: 0.628

5.  S2k guideline on diagnosis and treatment of atopic dermatitis--short version.

Authors:  Thomas Werfel; Annice Heratizadeh; Werner Aberer; Frank Ahrens; Matthias Augustin; Tilo Biedermann; Thomas Diepgen; Regina Fölster-Holst; Uwe Gieler; Julia Kahle; Alexander Kapp; Alexander Nast; Katja Nemat; Hagen Ott; Bernhard Przybilla; Martin Roecken; Martin Schlaeger; Peter Schmid-Grendelmeier; Jochen Schmitt; Thomas Schwennesen; Doris Staab; Margitta Worm
Journal:  J Dtsch Dermatol Ges       Date:  2016-01       Impact factor: 5.584

6.  Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.

Authors:  C Mailhol; V Lauwers-Cances; F Rancé; C Paul; F Giordano-Labadie
Journal:  Allergy       Date:  2009-01-31       Impact factor: 13.146

Review 7.  Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature.

Authors:  A C A Devillers; A P Oranje
Journal:  Br J Dermatol       Date:  2006-04       Impact factor: 9.302

8.  Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.

Authors:  Jennifer T Huang; Melissa Abrams; Brook Tlougan; Alfred Rademaker; Amy S Paller
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

9.  Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to T cells in vitro.

Authors:  R S Kalish; J A Wood; A LaPorte
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

10.  Early molecular events in the induction phase of contact sensitivity.

Authors:  A H Enk; S I Katz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.